Back to news

Why Viking Therapeutics (VKTX) Stock Is Up Today

Investivoq PriceTracker

Viking Therapeutics (VKTX) is up 4.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be renewed interest in Viking’s obesity pipeline ahead of near-term scientific visibility, especially after the company said it will present two VK2735 posters at ObesityWeek 2026. This could also be because investors are still digesting the company’s recent pipeline update and large cash position, which support continued development of its lead obesity program. ([prnewswire.com](https://www.prnewswire.com/news-releases/viking-therapeutics-announces-two-poster-presentations-at-obesityweek-2026-302932884.html?utm_source=openai))

Details:

  • Viking said on November 9 that it will present two posters on VK2735 at ObesityWeek 2026 in Washington, D.C., with presentations scheduled for November 14 and November 15. ([prnewswire.com](https://www.prnewswire.com/news-releases/viking-therapeutics-announces-two-poster-presentations-at-obesityweek-2026-302932884.html?utm_source=openai))
  • The company’s late-October corporate update highlighted encouraging earlier VK2735 data and laid out upcoming clinical and scientific milestones, keeping attention on the obesity franchise. ([ir.vikingtherapeutics.com](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update?utm_source=openai))
  • Viking ended the third quarter with about $960 million in cash, cash equivalents, and investments after completing equity and convertible note offerings, reducing near-term financing pressure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436145/vktx-ex99_1.htm?utm_source=openai))
  • There does not appear to be a fresh SEC filing or major announced partnership tied directly to today’s move, so the gain looks more consistent with catalyst positioning and momentum in obesity-drug names than with a single definitive headline. ([ir.vikingtherapeutics.com](https://ir.vikingtherapeutics.com/sec-filings?utm_source=openai))

    • Sources:

    PR Newswire, SEC, Viking Therapeutics Investor Relations

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $VKTX Insider Trading Activity

    VKTX Insider Trades

    $VKTX insiders have traded $VKTX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

    Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:

    • BRIAN LIAN (President & CEO) sold 148,517 shares for an estimated $4,947,888
    • GREG ZANTE (Chief Financial Officer) sold 21,217 shares for an estimated $710,141
    • MARIANNA MANCINI (Chief Operating Officer) sold 18,217 shares for an estimated $609,635

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive VKTX Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $VKTX Hedge Fund Activity

    We have seen 226 institutional investors add shares of $VKTX stock to their portfolio, and 206 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • FMR LLC added 3,511,261 shares (+55.4%) to their portfolio in Q3 2026, for an estimated $114,467,108
    • JPMORGAN CHASE & CO removed 855,676 shares (-93.5%) from their portfolio in Q3 2026, for an estimated $27,895,037
    • BARCLAYS PLC added 819,705 shares (+1546.9%) to their portfolio in Q3 2026, for an estimated $26,722,383
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. removed 730,690 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $23,820,494
    • BLACKROCK, INC. removed 690,641 shares (-10.0%) from their portfolio in Q2 2026, for an estimated $26,941,905
    • JUMP FINANCIAL, LLC added 579,882 shares (+inf%) to their portfolio in Q2 2026, for an estimated $22,621,196
    • TWO SIGMA INVESTMENTS, LP removed 494,728 shares (-11.2%) from their portfolio in Q2 2026, for an estimated $19,299,339

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $VKTX Analyst Ratings

    Wall Street analysts have issued reports on $VKTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Canaccord Genuity issued a "Buy" rating on 10/30/2026
    • UBS issued a "Buy" rating on 10/15/2026
    • Truist Securities issued a "Buy" rating on 10/07/2026
    • JP Morgan issued a "Overweight" rating on 08/11/2026

    To track analyst ratings and price targets for $VKTX, check out Investivoq's $VKTX forecast page.

    $VKTX Price Targets

    Multiple analysts have issued price targets for $VKTX recently. We have seen 5 analysts offer price targets for $VKTX in the last 6 months, with a median target of $89.0.

    Here are some recent targets:

    • Edward Nash from Canaccord Genuity set a target price of $118.0 on 10/30/2026
    • Joon Lee from UBS set a target price of $94.0 on 10/15/2026
    • Joon Lee from Truist Securities set a target price of $85.0 on 10/07/2026
    • Hardik Parikh from JP Morgan set a target price of $65.0 on 08/11/2026
    • Daniel Brims from Lake Street set a target price of $89.0 on 05/28/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.